daclizumab (Zenapax)
daclizumab is an FDA-licensed reference biologic from Hoffmann-La Roche Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
1997
Reference approved
Reference product
Zenapax daclizumab
Hoffmann-La Roche Inc.
- Approved
- Dec 10, 1997
- Marketing
- Disc
- Center
- CDER
- Patents
- None listed
Molecular structure
Experimental 3D structure for daclizumab from the RCSB Protein Data Bank (PDB 3NFS).
Interactive biological assembly from PDB entry 3NFS. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here — no need to leave the page.
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for daclizumab, in chronological order.
Reference approval
Approval date of the reference daclizumab product.
28 yr 11 mo ago
Frequently asked questions
Are there biosimilars approved for daclizumab (Zenapax)?
No 351(k) biosimilars or interchangeable biosimilars referencing daclizumab are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.